http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-611145-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f26dbe20d4266eacb686db68d52c2048 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2031 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-77 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-765 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-77 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-765 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2011-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba460ed84ee31840aaec32b87563addc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25a4d567bf4d3ab14dad1a1936dd5637 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f813a4bb87e790518abb14a067d0ec33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d23aa2e1e8b569c1ee20d65d648b0d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa74bc07f918e88ef32aa56f26d22cf1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bbc435ad4d0b32d6c9effc356caa1e21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51ce5730dbb73f1583624aab84b5d224 |
| publicationDate | 2015-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-611145-A |
| titleOfInvention | Peg or peg block copolymers for treating colorectal cancer |
| abstract | Disclosed is the use of a composition comprising polyethylene glycol (PEG) or PEG block copolymer in the manufacture of a medicament for use in a method for treating, ameliorating and/or preventing colorectal cancer (CRC) in humans wherein the method comprises administering approximately between 800 grams and 2365 grams of PEG or PEG block co-polymer over a period of 18 to 36 consecutive calendar months. Also disclosed is the use of a composition comprising polyethylene glycol (PEG) or PEG block copolymer in the manufacture of a medicament for use in a method of treating, ameliorating and/or preventing colorectal cancer (CRC) in humans, wherein the method comprises administering between 0.2 and 6.4 grams of PEG or PEG block co-polymer on a daily basis, wherein approximately 800 grams or greater of PEG or PEG block co-polymer is administered over a period of 24 or 36 consecutive calendar months, and wherein the composition comprises: (a) 50 – 90 % w/w polyethylene glycol (PEG), having an average molecular weight within the range 2,000 to 10,000 Da; and (b) 10 – 40 % w/w of a solid selected from the group consisting of: sorbitol, lactose, lactose and starch, dextrates, cellulose, xylitol, maltitol and mannitol; and (c) optionally further excipients optionally including flavourings, sweeteners and lubricants. |
| priorityDate | 2010-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.